Distinguishing Features of Cetuximab and Panitumumab in Colorectal Cancer and Other Solid Tumors.

Front Oncol · 2019 · PMC6763619 · PMID 31616627

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

bevacizumab-based treatment in RAS wt left-sided mCRC are available only from the phase 2 PEAK study, in which OS trended toward improvement with panitumumab; however, the results did not reach statistical significance ( 96 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.